-
ESTABLISHING A LEADER IN CELL-BASED IMMUNOTHERAPIES BUILT ON DECADES OF EXPERTISE IN THE FIELD OF ALLOGENEIC DENDRITIC CELL BIOLOGY
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
About us
Developing innovative cancer immunotherapies
Immunicum is advancing novel cell-based approaches to treat blood-borne and solid tumors.
Learn more
Press Releases
Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study
03 Dec 2021Immunicum and PCI Biotech Announce an Extension to Their Research Collaboration to Explore Novel Cancer Vaccination Treatments
30 Nov 2021Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells
22 Nov 2021
On Monday, November 15, interested shareholders had the chance to meet and talk with Immunicum's CEO Erik Manting and CFO Lotta Ferm at Immunicum's Meet and Greet event in Stockholm. We greatly appreciated the presence and engagement of the attendees and look forward to organizing similar events in the future.
Podcast about cell and gene therapy featuring Immunicum CEO Erik Manting
News
-
European Hematology Association (EHA) 2021 Virtual Meeting – Posters
11 Jun 2021 -
Immunicum Corporate Presentation at Redeye Growth Day 2021
8 Jun 2021 -
Immunicum Investor Event on April 22, 2021 at 1:00 pm CET
19 Apr 2021 -
Virtual Investor Event Materials
8 Dec 2020 -
Transaction Webcast Presentation
19 Nov 2020
